Here is the valuation report mentioned in the newsletter -
Valuation updated to 0.99
Updated valuation to 0.99, which does not even include CDH17. "Because the CDH17 programme is not yet in the clinic, we are not including it in our valuation yet, in accordance with Edison methodology."
https://www.edisongroup.com/wp-content/uploads/2021/07/Chimeric-Therapeutics-Acquiring-a-promising-first-in-class-CAR-T-asset-1.pdf
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $50.77K | 12.69M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2602327 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 18629873 | 23 |
View Market Depth
| Last trade - 15.15pm 25/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |